Science:罕见遗传病诊断——转录组分析技术再下一城

2019-10-19 Blake 转化医学网

近年来,随着测序技术的飞速发展,多组学分析技术在疾病的诊断中应用越来越广泛。然而,在罕见遗传病的检测中依然有诸多限制。近日,来自哥伦比亚大学的研究人员开发了一种等位基因表达失衡分析技术,能够通过分析两个等位基因的表达失衡来诊断罕见疾病。通过联合其它技术,其将在罕见遗传病的诊断和机理研究中发挥重要作用。

近年来,随着测序技术的飞速发展,多组学分析技术在疾病的诊断中应用越来越广泛。然而,在罕见遗传病的检测中依然有诸多限制。近日,来自哥伦比亚大学的研究人员开发了一种等位基因表达失衡分析技术,能够通过分析两个等位基因的表达失衡来诊断罕见疾病。通过联合其它技术,其将在罕见遗传病的诊断和机理研究中发挥重要作用。



目前,可通过对人类外显子组和基因组参考数据库的分析来鉴别人类基因组变异。这些分析可发现导致孟德尔遗传病的编码区突变,并可为25-50%的患者提供基因诊断。然而,由于很难鉴定一些罕见的调节基因以及其下游靶基因,对DNA测序数据的分析并不能解释非编码区突变引起的罕见病。
 
整合基因组和转录组数据可以更好地对罕见变异的影响进行诊断。但是,由于这些转录组受到复杂因素如环境、疾病状态、测序技术的影响,这种分析往往非常耗时耗力。因此,大部分分析仅限于一小部分很明显的突变,比如完全不表达和剪接缺陷,却很难量化某一突变是否超出了正常范围。

哥伦比亚大学的研究人员开发的这种等位基因表达失衡分析方法,能够通过分析两个等位基因的表达失衡来诊断罕见疾病,该研究发表在近日的《Science》上。该方法可定量判断一个人的基因表达是否处于正常水平,尤其是可以检测罕见调节元件变异引起的基因表达失衡。

等位基因特异性表达(allelic expression,AE),即等位基因失衡,可用于对孟德尔遗传病的鉴定和诊断,即通过对源来自父本和母本的等位基因的表达水平差异分析,检测罕见遗传病患者正常范围之外的基因。罕见遗传病的变异基因通常由单等位基因表达异常表达导致。对于等位基因失衡导致的表型变异,环境和技术因素影响很小,遗传因素作用占85%,因此对顺式作用元件的检测具有更高的敏感度。
 
在该研究中,Pejman Mohammad博士及其小组成员开发了一种等位基因表达失衡分析方法——ANEVA(表达变异分析, analysis of expression variation),并基于此开发了ANEVA-DOT方法。该方法基于转录组测序及组织特异性基因表达GTEx数据库,可有效提高罕见基因变异检测效率。

为了测试ANEVA-DOT方法的效果,研究人员将ANEVA-DOT方法在70名孟德尔肌肉疾病(Men-delian muscle dystrophy and myopathy,MDM)患者的等位基因特异性表达数据上进行了测试。结果表明,ANEVA-DOT技术成功的检测出了已确诊患者的表达失衡的致病基因,在许多未确诊的患者中,ANEVA-DOT技术发现了多个肌肉疾病相关的基因,其中一个后来被证实是一个致病基因。



ANEVA-DOT是一个快速发现罕见遗传病致病基因的强大工具,可从少量临床样本中得出结果,由于ANEVA-DOT可通过转录组数据中得到结果,而不必检测引起下游基因表达变化的罕见调节元件变异,因而ANEVA-DOT技术在未知调节元件变异引起的遗传病检测中具有独特的优势。结合GTEx中的参考数据,ANEVA-DOT可以应用于临床上罕见疾病的诊断。
 
ANEVA-DOT也有一些限制性,比如只适用于具有asSNP的患者的大约一半的表达基因上。因此,正如其它的基因诊断技术,ANEVA-DOT也需要联合其它技术来鉴定引起遗传病的罕见基因变异。
 
目前,该研究团队正与多家医院合作,并将ANEVA-DOT应用于多种罕见疾病中,如神经系统疾病、肌肉疾病,这些研究将进一步完善该方法。相信在以后的临床遗传学中,对转录组数据的分析将成为鉴定疾病相关基因变异的有力工具。

原始出处:

Pejman Mohammadi, Stephane E. Castel, Beryl B. Cummings, et.al. Genetic regulatory variation in populations informs transcriptome analysis in rare disease. Science 18 Oct 2019:Vol. 366, Issue 6463, pp. 351-356

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1654137, encodeId=fbff165413e22, content=<a href='/topic/show?id=98f4933e0cd' target=_blank style='color:#2F92EE;'>#转录组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93370, encryptionId=98f4933e0cd, topicName=转录组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07e724453575, createdName=zhangyxzsh, createdTime=Fri Dec 27 00:52:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968946, encodeId=895719689460e, content=<a href='/topic/show?id=893de9586ba' target=_blank style='color:#2F92EE;'>#罕见遗传病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79586, encryptionId=893de9586ba, topicName=罕见遗传病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Sun Feb 09 22:52:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747376, encodeId=f15b1e47376dc, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Mar 08 06:52:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375990, encodeId=009513e59906b, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Mon Oct 21 02:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420194, encodeId=043914201946b, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Mon Oct 21 02:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467495, encodeId=75da146e49554, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Mon Oct 21 02:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1654137, encodeId=fbff165413e22, content=<a href='/topic/show?id=98f4933e0cd' target=_blank style='color:#2F92EE;'>#转录组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93370, encryptionId=98f4933e0cd, topicName=转录组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07e724453575, createdName=zhangyxzsh, createdTime=Fri Dec 27 00:52:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968946, encodeId=895719689460e, content=<a href='/topic/show?id=893de9586ba' target=_blank style='color:#2F92EE;'>#罕见遗传病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79586, encryptionId=893de9586ba, topicName=罕见遗传病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Sun Feb 09 22:52:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747376, encodeId=f15b1e47376dc, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Mar 08 06:52:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375990, encodeId=009513e59906b, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Mon Oct 21 02:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420194, encodeId=043914201946b, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Mon Oct 21 02:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467495, encodeId=75da146e49554, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Mon Oct 21 02:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1654137, encodeId=fbff165413e22, content=<a href='/topic/show?id=98f4933e0cd' target=_blank style='color:#2F92EE;'>#转录组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93370, encryptionId=98f4933e0cd, topicName=转录组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07e724453575, createdName=zhangyxzsh, createdTime=Fri Dec 27 00:52:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968946, encodeId=895719689460e, content=<a href='/topic/show?id=893de9586ba' target=_blank style='color:#2F92EE;'>#罕见遗传病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79586, encryptionId=893de9586ba, topicName=罕见遗传病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Sun Feb 09 22:52:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747376, encodeId=f15b1e47376dc, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Mar 08 06:52:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375990, encodeId=009513e59906b, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Mon Oct 21 02:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420194, encodeId=043914201946b, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Mon Oct 21 02:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467495, encodeId=75da146e49554, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Mon Oct 21 02:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
    2020-03-08 mjldent
  4. [GetPortalCommentsPageByObjectIdResponse(id=1654137, encodeId=fbff165413e22, content=<a href='/topic/show?id=98f4933e0cd' target=_blank style='color:#2F92EE;'>#转录组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93370, encryptionId=98f4933e0cd, topicName=转录组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07e724453575, createdName=zhangyxzsh, createdTime=Fri Dec 27 00:52:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968946, encodeId=895719689460e, content=<a href='/topic/show?id=893de9586ba' target=_blank style='color:#2F92EE;'>#罕见遗传病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79586, encryptionId=893de9586ba, topicName=罕见遗传病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Sun Feb 09 22:52:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747376, encodeId=f15b1e47376dc, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Mar 08 06:52:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375990, encodeId=009513e59906b, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Mon Oct 21 02:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420194, encodeId=043914201946b, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Mon Oct 21 02:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467495, encodeId=75da146e49554, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Mon Oct 21 02:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
    2019-10-21 jichang
  5. [GetPortalCommentsPageByObjectIdResponse(id=1654137, encodeId=fbff165413e22, content=<a href='/topic/show?id=98f4933e0cd' target=_blank style='color:#2F92EE;'>#转录组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93370, encryptionId=98f4933e0cd, topicName=转录组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07e724453575, createdName=zhangyxzsh, createdTime=Fri Dec 27 00:52:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968946, encodeId=895719689460e, content=<a href='/topic/show?id=893de9586ba' target=_blank style='color:#2F92EE;'>#罕见遗传病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79586, encryptionId=893de9586ba, topicName=罕见遗传病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Sun Feb 09 22:52:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747376, encodeId=f15b1e47376dc, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Mar 08 06:52:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375990, encodeId=009513e59906b, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Mon Oct 21 02:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420194, encodeId=043914201946b, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Mon Oct 21 02:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467495, encodeId=75da146e49554, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Mon Oct 21 02:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1654137, encodeId=fbff165413e22, content=<a href='/topic/show?id=98f4933e0cd' target=_blank style='color:#2F92EE;'>#转录组分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93370, encryptionId=98f4933e0cd, topicName=转录组分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=07e724453575, createdName=zhangyxzsh, createdTime=Fri Dec 27 00:52:00 CST 2019, time=2019-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968946, encodeId=895719689460e, content=<a href='/topic/show?id=893de9586ba' target=_blank style='color:#2F92EE;'>#罕见遗传病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79586, encryptionId=893de9586ba, topicName=罕见遗传病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d74253, createdName=wangtianj2007@, createdTime=Sun Feb 09 22:52:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747376, encodeId=f15b1e47376dc, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Mar 08 06:52:00 CST 2020, time=2020-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375990, encodeId=009513e59906b, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Mon Oct 21 02:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1420194, encodeId=043914201946b, content=<a href='/topic/show?id=5f3a9336904' target=_blank style='color:#2F92EE;'>#转录组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93369, encryptionId=5f3a9336904, topicName=转录组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c9e3571203, createdName=marlenexl, createdTime=Mon Oct 21 02:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1467495, encodeId=75da146e49554, content=<a href='/topic/show?id=ef32e9539e8' target=_blank style='color:#2F92EE;'>#罕见#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79539, encryptionId=ef32e9539e8, topicName=罕见)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29f36868190, createdName=syscxl, createdTime=Mon Oct 21 02:52:00 CST 2019, time=2019-10-21, status=1, ipAttribution=)]
    2019-10-21 syscxl